Stockscreener 앱 받기
29.83
4.05%
-1.352
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heart drug developer NewAmsterdam opens March investor webcasts - Stock Titan
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat
Published on: 2026-02-22 03:05:00 - baoquankhu1.vn
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru
What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat
6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia
Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Ideas Watch: What are NewAmsterdam Pharma Company NVs technical support levels2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aberdeen Group plc Has $18.83 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Needham & Company LLC Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insi - GuruFocus
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co - Benzinga
Earnings Summary: NewAmsterdam Pharma Co Q4 - Benzinga
NewAmsterdam Pharma Narrows Net Loss in 2025, Revenue Drops - marketscreener.com
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Earnings Flash (NAMS) NewAmsterdam Pharma Posts FY 2025 Revenue $22.5M versus $45.6M a Year Ago - marketscreener.com
NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges - DirectorsTalk Interviews
Published on: 2026-02-17 13:42:01 - mfd.ru
Viking Global discloses 3.7% NewAmsterdam Pharma (NAMS) holding in 13G/A - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC - MarketBeat
Can NewAmsterdam Pharma Company N.V. Equity Warrant be the next market leaderJuly 2025 Setups & Smart Swing Trading Alerts - mfd.ru
Why (NAMS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit - Yahoo Finance
What insider trading reveals about NewAmsterdam Pharma Company N.V. Equity Warrant stockQuarterly Market Review & Fast Moving Stock Trade Plans - mfd.ru
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock going upMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Published on: 2026-02-11 17:43:14 - mfd.ru
NAMSNewAmsterdam Pharma Company N.V Latest Stock News & Market Updates - Stock Titan
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 40% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Momentum Shift: Should I trade or invest in NewAmsterdam Pharma Company NV2025 Support & Resistance & Reliable Momentum Entry Alerts - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants - National Today
Breakouts Watch: Will NewAmsterdam Pharma Company NV benefit from sector rotationBond Market & Fast Gain Stock Tips - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
0.50%
자본화:
|
볼륨(24시간):